SIEMENS MEDICAL SOLUTIONS USA, INC

Lobbying for SIEMENS MEDICAL SOLUTIONS USA, INC

Filing 4th Quarter - Report

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Jan 20, 2026

Expenses

$720,000.00

What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

District of Columbia

Official filing document

Government bodies contacted 4

Commerce, Dept of (DOC)
HOUSE OF REPRESENTATIVES
Natl Security Council (NSC)
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 17

HR 5343
Ensuring Patient Access to Critical Breakthrough Products Act
S 1717
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
HR 6197
Health Tech Investment Act
S 1399
Health Tech Investment Act
HR 5269
RESULTS Act
S 2761
RESULTS Act
HR 1406
Lung Cancer Screening and Prevention Act of 2025
HR 2319
Women and Lung Cancer Research and Preventive Services Act of 2025
S 1157
Women and Lung Cancer Research and Preventive Services Act of 2025
HR 4417
Mobile Cancer Screening Act
S 2927
Mobile Cancer Screening Act
HR 4121
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
S 2256
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
HR 5304
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
HR 5371
Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions …
S 2882
Continuing Appropriations and Extensions and Other Matters Act, 2026
HR 3838
Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 20…

Lobbying activity 6

Health Issues

Issues related to FDA & third-party regulation of AI and Machine Learning-enabled devices; Issues related to Artificial Intelligence for medical devices; Issues related to data privacy standards and transparency.

Medicare/Medicaid

H.R. 5343 / S. 1717 - Ensuring Patient Access to Critical Breakthrough Products Act of 2025 H.R. 6197 / S. 1399 - Health Tech Investment Act; H.R. 5269 / S. 2761 - Reforming and Enhancing Sustainable Updates to Laboratory Testing Services Act of 2025 H.R. 1406 - Lung Cancer Screening and Prevention Act of 2025;H.R. 2319 / S. 1157 - Woman and Lung Cancer Research and Preventive Services Act of 2025; H.R. 5269 / S. 2761 - Reforming and Enhancing Sustainable Updates to Laboratory Testing Services Act of 2025; H.R. 4417 / S. 2927 - Mobile Cancer Screening Act; and H.R. 5269 / S. 2761 - RESULTS Act. Issues related to Medicare reimbursement rates; and Issues related to Medicare site-neutral payments.

Budget/Appropriations

H.R. 4121 / S. 2256 / H. Rept 119-172 / S. Rept. 119-37 - Agriculture, Rural Development, Food and Drug Administration (FDA) Appropriation Act, FY 2026 - issues related to general and center specific FDA funding; H.R. 5304 / S. S587 / H. Rept. 119-271 / S. Rept. 117-55 - Labor-HHS-Education Appropriation Act, FY 2026; and P.L 119-37 / H.R.5371 / S. 2882 - Continuing Appropriations and Extensions Act, 2026.

Trade (domestic/foreign)

Issues related to medical supply chains and procurement; Issues related to critical minerals supply chains and production; and Issues related to international trade.

Tariff (miscellaneous tariff bills)

Issues related to tariffs and supply chain resilience; Issues related to tariffs on medical devices; and Implementation of P.L. 87-794 - Trade Expansion Act - issues related to Section 232.

Defense

P.L. 119-60 / H.R. 3838 / S 2296 / H.Rept 119-231 / S. Rept. 119-39- National Defense Authorization Act, 2026 - issues related to right to repair and BIOSECURE Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.